Virus meets antibody in early skin cancer fight
NCT ID NCT04163952
Summary
This early-stage study tested a two-part treatment for advanced skin cancer that had spread or returned. It combined a modified virus injected into the tumor to trigger the immune system with an antibody drug given by IV to block cancer growth. The main goals were to check the safety of this combination and see if it worked better than the antibody drug alone. The study was small and ended early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SKIN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
NYU Langone Medical Center (Tisch Hospital)
New York, New York, 10016, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.